Anthera Pharma (ANTH) Reports Positive Conclusion to DSMB Safety Review of Sollpura Phase 3

August 16, 2016 8:48 AM EDT
Get Alerts ANTH Hot Sheet
Trade ANTH Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had “no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter.”

This follows six positive reviews by a separate independent blisibimod DSMB for the CHABLIS-SC1 clinical study in patients with lupus and the BRIGHT-SC clinical study in patients with IgA nephropathy that recommended that the studies continue without modification, with the latest positive review occurring in June of this year.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News, Management Comments

Add Your Comment